EP Patent

EP3793591A1 — Anti-cd63 antibodies, conjugates, and uses thereof

Assigned to Regeneron Pharmaceuticals Inc · Expires 2021-03-24 · 5y expired

What this patent protects

Antibodies, portions, and fusion proteins thereof to CD63 are provided. Also provided are nucleic acid sequences encoding same. Also provided are compositions comprising and methods of using same, e.g., for treating a patient in need thereof.

USPTO Abstract

Antibodies, portions, and fusion proteins thereof to CD63 are provided. Also provided are nucleic acid sequences encoding same. Also provided are compositions comprising and methods of using same, e.g., for treating a patient in need thereof.

Drugs covered by this patent

Patent Metadata

Patent number
EP3793591A1
Jurisdiction
EP
Classification
—
Expires
2021-03-24
Drug substance claim
No
Drug product claim
No
Assignee
Regeneron Pharmaceuticals Inc
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.